Attana was founded in 2002 on the principle of characterizing molecular interactions exactly as they occur in the human body. Since then, we have developed proprietary label-free biosensor instruments for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform – a proprietary in-vitro diagnostics (IVD) tool.

With HQ in Stockholm, Sweden, and a research lab in London, UK, we develop and sell our proprietary products and services to Big Pharma, biotech companies and academic institutions within life science.

Our instruments are optimized for real-time analysis of crude samples and serum to provide biologically relevant information for more accurate diagnostics and improved efficiency and performance of the pharmaceutical drug development process. Our instruments can determine specificity, kinetics and affinity, among other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria. Our team of highly skilled and experienced application specialists, also routinely perform contract research for both industrial and academic customers.

Since the advent of COVID-19, we have worked closely with selected customers in their development of novel vaccine candidates and therapeutics. In these efforts, our instruments have further shown their reliability and versatility. As a result, we have launched the Attana Virus Analytics (AVA) platform and are also engaged in cross-disciplinary development of a diagnostic device based on our proprietary technology combined with AI-enabled automated analytic capabilities.